The continuum between healthy ageing and idiopathic Parkinson Disease within a propagation perspective of inflammation and damage: the search for new diagnostic, prognostic and therapeutic targets. Phase 2

The continuum between healthy ageing and idiopathic Parkinson Disease within a propagation perspective of inflammation and damage: the search for new diagnostic, prognostic and therapeutic targets. Phase 2 - PROPAG-AGEING - Phase 2

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00011260

Enrollment

560

Registered

2016-11-09

Start date

2016-09-06

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G20.9

Interventions

Group 1: Healthy siblings of Parkinson Disease patients, subdivided into a RBD-positive and -negative group, will be evaluated for the presence of clinical/neurological and molecular (genetic, epigene

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Siblings of patients with a diagnosis of sporadic idiopathic Parkinson’s Disease, according to the International Diagnostic Criteria [UK Brain Bank Criteria]; 2.signed informed consent

Exclusion criteria

Exclusion criteria: 1.Diagnosis of sporadic idiopathic Parkinson’s Disease according to the UK Brain Bank Criteria; 2.patients affected by clinically relevant diseases of the Central Nervous System (i.e. Alzheimer’s disease, Vascular Encephalopathies, Multiple Sclerosis, etc.).

Design outcomes

Primary

Measure	Time frame
To validate biomarkers for early diagnosis of Parkinson Disease	—

Countries

Germany, Italy, Spain, United Kingdom

Contacts

Public ContactClaudio Franceschi

IRCCS Istituto delle Scienze Neurologiche di Bologna

c.franceschi@ausl.bologna.it+39 051 4996075

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026